131 related articles for article (PubMed ID: 6935451)
1. Labeling index as a prognostic marker in non-Hodgkin's lymphomas.
Costa A; Bonadonna G; Villa E; Valagussa P; Silvestrini R
J Natl Cancer Inst; 1981 Jan; 66(1):1-5. PubMed ID: 6935451
[TBL] [Abstract][Full Text] [Related]
2. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
3. Morphological and clinical significance of cell kinetics in non-Hodgkin's lymphomas.
Del Bino G; Silvestrini R; Costa A; Veneroni S; Giardini R
Basic Appl Histochem; 1986; 30(2):197-202. PubMed ID: 3741316
[TBL] [Abstract][Full Text] [Related]
4. Non-hodgkin's lymphomas in Saskatchewan: a clinicopathologic study.
Cherian T; Skinnider LF; Wright JL; Komjathy G
Can Med Assoc J; 1978 Sep; 119(5):435-41. PubMed ID: 356951
[TBL] [Abstract][Full Text] [Related]
5. Treatment results of tonsillar lymphoma: a 10-year experience.
Mohammadianpanah M; Omidvai S; Mosalei A; Ahmadloo N
Ann Hematol; 2005 Apr; 84(4):223-6. PubMed ID: 15042316
[TBL] [Abstract][Full Text] [Related]
6. Outcome and prognostic factors in ocular adnexal lymphoma.
Nola M; Lukenda A; Bollmann M; Kalauz M; Petrovecki M; Bollmann R
Croat Med J; 2004 Jun; 45(3):328-32. PubMed ID: 15185428
[TBL] [Abstract][Full Text] [Related]
7. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of CD44v6 in diffuse large B-cell lymphoma.
Inagaki H; Banno S; Wakita A; Ueda R; Eimoto T
Mod Pathol; 1999 May; 12(5):546-52. PubMed ID: 10349995
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of p27KIP1 protein and ki-67 growth fraction in non-small cell lung cancers.
Hommura F; Dosaka-Akita H; Mishina T; Nishi M; Kojima T; Hiroumi H; Ogura S; Shimizu M; Katoh H; Kawakami Y
Clin Cancer Res; 2000 Oct; 6(10):4073-81. PubMed ID: 11051259
[TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of three subtypes of primary sinonasal lymphoma characterized by immunophenotypic analysis.
Kim GE; Koom WS; Yang WI; Lee SW; Keum KC; Lee CG; Suh CO; Hahn JS; Roh JK; Kim JH
Head Neck; 2004 Jul; 26(7):584-93. PubMed ID: 15229900
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of primary mediastinal large B-cell lymphomas].
Schneider T; Tóth E; Molnár Z; Várady E; Deák B; Horváth A; Horváth GI; Eid H; Schneider K; Lovey J; Keresztes S; Esik O; Lengyel Z; Rosta A
Orv Hetil; 2004 Dec; 145(50):2531-7. PubMed ID: 15662753
[TBL] [Abstract][Full Text] [Related]
12. Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma.
Broyde A; Boycov O; Strenov Y; Okon E; Shpilberg O; Bairey O
Am J Hematol; 2009 Jun; 84(6):338-43. PubMed ID: 19384938
[TBL] [Abstract][Full Text] [Related]
13. Autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas in first complete or partial remission: a retrospective analysis of the outcome of 52 patients according to the age-adjusted International Prognostic Index.
Fanin R; Silvestri F; Geromin A; Infanti L; Sperotto A; Cerno M; Stocchi R; Savignano C; Rinaldi C; Damiani D; Baccarani M
Bone Marrow Transplant; 1998 Feb; 21(3):263-71. PubMed ID: 9489649
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
[TBL] [Abstract][Full Text] [Related]
15. Nodular poorly differentiated lymphocytic lymphoma: changes in histology and survival.
Ostrow SS; Diggs CH; Sutherland JC; Gustafson J; Wiernik PH
Cancer Treat Rep; 1981; 65(11-12):929-33. PubMed ID: 7028254
[TBL] [Abstract][Full Text] [Related]
16. Pseudouridine: a prognostic marker in non-Hodgkin's lymphomas.
Rasmuson T; Björk GR
Cancer Detect Prev; 1985; 8(1-2):287-90. PubMed ID: 4064048
[TBL] [Abstract][Full Text] [Related]
17. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
[TBL] [Abstract][Full Text] [Related]
18. Primary intestinal lymphoma: clinical and therapeutic features of 32 patients.
Zinzani PL; Magagnoli M; Pagliani G; Bendandi M; Gherlinzoni F; Merla E; Salvucci M; Tura S
Haematologica; 1997; 82(3):305-8. PubMed ID: 9234576
[TBL] [Abstract][Full Text] [Related]
19. Malignant lymphoma: an update on diagnosis, staging, and management.
Perlin E
Prim Care; 1980 Sep; 7(3):409-22. PubMed ID: 6905202
[TBL] [Abstract][Full Text] [Related]
20. Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi.
Morabito F; Gallamini A; Stelitano C; Callea V; Guglielmi C; Neri S; Lazzaro A; Orsucci L; Ilariucci F; Sacchi S; Vitolo U; Federico M
Cancer; 2004 Oct; 101(7):1601-8. PubMed ID: 15378507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
